Valneva and Dynavax Technologies Corporation announced their collaboration to initiate a vaccine program for the current coronavirus, COVID-19.
- Valneva is leveraging its technical and platform capabilities to develop an inactivated, whole virus vaccine candidate against the current coronavirus threat
- Dynavax is providing CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, to support the development of Valneva´s COVID-19 vaccine candidate
- Valneva will seek grant funding to support the required investment for this program